The high prevalence of KRAS mutations has been identified to play an important role in the immunosuppressive TME in cancers, through actions such as inducing NLRP3 inflammasome activation and programmed death-ligand-1 (PD-L1) expression [35]. The gene discussed is CD274; the disease is cancer.